EA201791313A1 - Агенты, связывающие суперсемейство рецепторов фактора некроза опухоли (tnfrsf), и их применения - Google Patents

Агенты, связывающие суперсемейство рецепторов фактора некроза опухоли (tnfrsf), и их применения

Info

Publication number
EA201791313A1
EA201791313A1 EA201791313A EA201791313A EA201791313A1 EA 201791313 A1 EA201791313 A1 EA 201791313A1 EA 201791313 A EA201791313 A EA 201791313A EA 201791313 A EA201791313 A EA 201791313A EA 201791313 A1 EA201791313 A1 EA 201791313A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agents
polypeptides
tnfrsf
superfamily
applications
Prior art date
Application number
EA201791313A
Other languages
English (en)
Inventor
Остин Л. Герни
Original Assignee
Онкомед Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкомед Фармасьютикалс, Инк. filed Critical Онкомед Фармасьютикалс, Инк.
Publication of EA201791313A1 publication Critical patent/EA201791313A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Описаны полипептиды и агенты, которые связывают белок рецептора суперсемейства TNF, особенно агенты, которые специфично связывают GITR, OX40 или CD40. Указанные полипептиды или агенты могут включать слитые полипептиды, особенно полипептиды, содержащие GITRL, OX40L или CD40L, и/или биспецифические агенты. Также описаны способы применения указанных полипептидов или агентов для индукции и/или усиления иммунного ответа, а также способы лечения заболеваний, таких как рак.
EA201791313A 2015-02-03 2016-02-03 Агенты, связывающие суперсемейство рецепторов фактора некроза опухоли (tnfrsf), и их применения EA201791313A1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562111404P 2015-02-03 2015-02-03
US201562153272P 2015-04-27 2015-04-27
US201562154008P 2015-04-28 2015-04-28
US201562218956P 2015-09-15 2015-09-15
US201562259129P 2015-11-24 2015-11-24
PCT/US2016/016306 WO2016126781A1 (en) 2015-02-03 2016-02-03 Tnfrsf-binding agents and uses thereof

Publications (1)

Publication Number Publication Date
EA201791313A1 true EA201791313A1 (ru) 2018-02-28

Family

ID=56564627

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791313A EA201791313A1 (ru) 2015-02-03 2016-02-03 Агенты, связывающие суперсемейство рецепторов фактора некроза опухоли (tnfrsf), и их применения

Country Status (18)

Country Link
US (2) US9724390B2 (ru)
EP (1) EP3253890A4 (ru)
JP (1) JP2018508233A (ru)
KR (1) KR20170108073A (ru)
CN (2) CN107406878A (ru)
AU (1) AU2016215394A1 (ru)
BR (1) BR112017016705A2 (ru)
CA (1) CA2975596A1 (ru)
CO (1) CO2017008047A2 (ru)
EA (1) EA201791313A1 (ru)
HK (1) HK1243741A1 (ru)
IL (1) IL253433A0 (ru)
MA (1) MA41460A (ru)
MX (1) MX2017009793A (ru)
PH (1) PH12017501372A1 (ru)
SG (1) SG11201706268XA (ru)
TW (1) TW201643184A (ru)
WO (1) WO2016126781A1 (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2310509T1 (sl) * 2008-07-21 2015-07-31 Apogenix Gmbh TNFSF enoverižne molekule
WO2014055897A2 (en) * 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
BR112016001114B1 (pt) 2013-07-19 2023-02-14 Vib Vzw Composição compreendendo uma proteína de fusão e uso da referida composição
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
RU2714157C2 (ru) * 2015-02-06 2020-02-12 Хит Байолоджикс, Инк. Вектор, коэкспрессирующий молекулы для вакцинации и костимулирующие молекулы
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
MX2018004022A (es) 2015-10-01 2018-09-11 Heat Biologics Inc Composiciones y metodos para unir dominios extracelulares de tipo i y tipo ii como proteinas quimericas heterologas.
CA3004830A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
CN109153729A (zh) * 2016-05-13 2019-01-04 免疫医疗有限责任公司 Cd40l-fc融合多肽及其使用方法
US11091557B2 (en) 2016-07-14 2021-08-17 Genmab A/S Methods of producing multispecific antibodies against CD40 and CD137
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
CN117586403A (zh) 2016-10-11 2024-02-23 艾吉纳斯公司 抗lag-3抗体及其使用方法
WO2018071405A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
US20200291089A1 (en) * 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
JP7121029B2 (ja) * 2017-02-27 2022-08-17 シャタック ラボ，インコーポレイテッド Ｃｓｆ１ｒベースのキメラタンパク質
AU2018224852A1 (en) 2017-02-27 2019-07-11 Shattuck Labs, Inc. VSIG8-based chimeric proteins
JP7260477B2 (ja) 2017-02-27 2023-04-18 シャタック ラボ，インコーポレイテッド Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
WO2018160572A1 (en) * 2017-02-28 2018-09-07 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising gitr-binding agents
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
WO2018205936A1 (zh) * 2017-05-08 2018-11-15 上海津曼特生物科技有限公司 双特异性重组蛋白及其应用
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
WO2018222949A1 (en) 2017-06-01 2018-12-06 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
KR102371420B1 (ko) * 2017-06-27 2022-03-08 (주)아모레퍼시픽 Tnfsf14 단백질을 포함하는 미백용 조성물
WO2019032945A1 (en) * 2017-08-10 2019-02-14 Oncomed Pharmaceuticals, Inc. CD40 BINDING AGENT AND USES THEREOF
EP3732197A1 (en) * 2017-12-28 2020-11-04 Julius-Maximilians-Universität Würzburg TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCyR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCyR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
WO2019237383A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 用于人 tnfsf18 基因编辑的修饰载体、其制备方法及应用
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
CN109912717B (zh) * 2019-03-04 2020-05-26 北京天广实生物技术股份有限公司 结合cd40的抗体及其用途
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
US20230212260A1 (en) * 2020-05-15 2023-07-06 Apogenix Ag Multi-specific immune modulators
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
WO2022192657A2 (en) * 2021-03-12 2022-09-15 Janssen Biotech, Inc. Bioengineered immunomodulatory fusion protein compositions
WO2023088876A1 (en) * 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325224B1 (en) * 1988-01-22 1996-07-31 ZymoGenetics, Inc. Methods of producing secreted receptor analogs
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
DE69332981T2 (de) 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
WO1998007880A1 (en) 1996-08-16 1998-02-26 Human Genome Sciences, Inc. Human endokine alpha
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
US5998171A (en) 1996-08-16 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human endokine alpha
DE69840413D1 (de) 1997-11-18 2009-02-12 Genentech Inc Dna 19355 polypeptide, ein homolog des tumornekrosefaktors
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
ES2315008T5 (es) 1998-02-24 2012-03-06 Sisters Of Providence In Oregon Agente de unión a receptor ox-40 para su uso en métodos de mejora de la respuesta inmune espec�?fica de ant�?geno tumoral.
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
CA2378179A1 (en) 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
US20080050809A1 (en) 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
WO2001025277A1 (en) 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
DE10122140A1 (de) 2001-05-08 2002-11-28 Apotech Res & Dev Ltd Rekombinante Fusionsproteine und deren Trimere
WO2003006058A1 (en) 2001-07-12 2003-01-23 Wyeth Cd25+ differential markers and uses thereof
AU2002366433A1 (en) 2001-08-16 2003-09-09 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
AU2002333502A1 (en) 2002-02-10 2003-09-04 Apoxis Sa Fusion constructs containing active sections of tnf ligands
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
US20070015271A1 (en) 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
EP3287144A1 (en) 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Immunopotentiating compositions
EP2277532A1 (en) 2002-09-11 2011-01-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
AU2003277828B2 (en) 2002-10-29 2009-06-04 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
CA2525717A1 (en) 2003-05-23 2004-12-09 Wyeth Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US7268116B2 (en) 2003-10-02 2007-09-11 Genhunter Corp. Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
JP5303146B2 (ja) 2004-10-06 2013-10-02 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｂ７−ｈ１ならびに癌の診断、予後診断および処置の方法
CA2585776A1 (en) 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
ES2432091T5 (es) 2005-03-25 2022-03-18 Gitr Inc Moléculas de unión GITR y usos de las mismas
SI1877090T1 (sl) 2005-05-06 2014-12-31 Providence Health System Trimerni fuzijski protein OY40-imunoglobulina in postopki uporabe
ES2772674T3 (es) 2005-05-12 2020-07-08 Zymogenetics Inc Composiciones y métodos para modular respuestas inmunitarias
SI1907000T2 (sl) 2005-06-08 2020-07-31 Dana-Farber Cancer Institute Postopki in sestavki za zdravljenje persistentne HIV infekcije z inhibicijo programiranih celični smrtnih 1 (PD-1) poti
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
WO2007084559A2 (en) 2006-01-13 2007-07-26 Board Of Regents, The University Of Texas System Methods to treat disease states by influencing the signaling of ox40-receptors and high throughput screening methods for identifying substances therefor
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
WO2007111931A2 (en) 2006-03-22 2007-10-04 Imperial Innovations Limited Compositions and methods relating to modulation of immune system components
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
EP2133365B1 (en) 2006-12-27 2017-05-17 Emory University Compositions and methods for the treatment of infections and tumors
EP2009022A1 (en) 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
CA2860950C (en) 2007-07-10 2017-08-01 Apogenix Gmbh Tnf superfamily collectin fusion proteins
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
US20090136446A1 (en) 2007-11-02 2009-05-28 Ludwig Institute For Cancer Research Ltd. Induction of regulatory t cell-resistant helper cd4+ t cells
MX364200B (es) 2008-04-09 2019-04-16 Genentech Inc Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
SI2310509T1 (sl) * 2008-07-21 2015-07-31 Apogenix Gmbh TNFSF enoverižne molekule
WO2010030002A1 (ja) 2008-09-12 2010-03-18 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
MX2011005691A (es) 2008-11-28 2011-07-20 Univ Emory Metodos para el tratamiento de infecciones y tumores.
ES2593049T3 (es) 2009-01-09 2016-12-05 Apogenix Ag Proteínas de fusión que forman trímeros
CN102421913A (zh) 2009-03-13 2012-04-18 宾夕法尼亚大学董事会 Ox40/trail融合蛋白
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
KR101573109B1 (ko) 2009-11-24 2015-12-01 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
IL300733A (en) 2010-03-05 2023-04-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeting immune modulation
US8461311B2 (en) 2010-06-08 2013-06-11 Washington University TRAIL trimers, methods and uses therefor
MY171312A (en) 2010-08-23 2019-10-08 Univ Texas Anti-ox40 antibodies and methods of using the same
JP6047142B2 (ja) * 2011-04-01 2016-12-21 ウニヴェルズィテート シュトゥットガルト 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用
US20140335050A1 (en) 2011-05-27 2014-11-13 The General Hospital Corporation Methods, compositions, and kits for the treatment of cancer
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
AU2013201121A1 (en) 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
US20150073043A1 (en) 2012-01-19 2015-03-12 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Use of phosphorylation pathway-related factor in regulating function of regulatory t cell
EP2812022B1 (en) 2012-02-06 2019-06-26 Providence Health & Services - Oregon Method of monitoring cancer treatment using ox40 agonists
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
ES2848052T3 (es) 2012-08-03 2021-08-05 Dana Farber Cancer Inst Inc Anticuerpos de unión dual anti-PD-L1 y PD-L2 de agente individual y métodos de uso
US10081759B2 (en) 2012-10-09 2018-09-25 Eric John Wernimont Method, apparatus, and composition for increased recovery of hydrocarbons by paraffin and asphaltene control from reaction of fuels and selective oxidizers in the subterranean environment
BR112015012644A2 (pt) 2012-11-30 2017-12-19 Hoffmann La Roche método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
EP3508215A3 (en) 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
CN105026424A (zh) 2013-01-01 2015-11-04 卡尔医疗有限公司 稳定形式的信号转化蛋白融合蛋白、及其使用和制备的方法
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
AR095363A1 (es) 2013-03-15 2015-10-14 Genentech Inc Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
WO2014145355A1 (en) * 2013-03-15 2014-09-18 Stone Geoffrey W Composition comprised of antigen linked to a tnf superfamily ligand
PL3021869T3 (pl) 2013-07-16 2020-11-16 F. Hoffmann-La Roche Ag Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi PD-1 i inhibitorów TIGIT
BR112016001114B1 (pt) 2013-07-19 2023-02-14 Vib Vzw Composição compreendendo uma proteína de fusão e uso da referida composição
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
WO2015038538A1 (en) 2013-09-10 2015-03-19 Medimmune, Llc Compositions and methods for treating sepsis
WO2015197874A2 (en) 2014-06-27 2015-12-30 Apogenix Gmbh Combination of cd95/cd95l inhibition and cancer immunotherapy
US9914761B2 (en) 2014-07-10 2018-03-13 Washington University Oligomers for TNF superfamily inhibition
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TW201625270A (zh) 2014-11-11 2016-07-16 梅迪繆思有限公司 用於治療贅瘤形成的治療組合及方法
MY191428A (en) 2014-11-14 2022-06-27 Hoffmann La Roche Antigen binding molecules comprising a tnf family ligand trimer
WO2016112983A1 (en) 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
CN114751989A (zh) 2015-03-31 2022-07-15 豪夫迈·罗氏有限公司 包含三聚体tnf家族配体的抗原结合分子
CN107709364A (zh) 2015-04-07 2018-02-16 豪夫迈·罗氏有限公司 具有激动剂活性的抗原结合复合体及使用方法
CA2992298A1 (en) 2015-07-23 2017-01-26 Inhibrx Lp Multivalent and multispecific gitr-binding fusion proteins
RU2018108236A (ru) 2015-08-12 2019-09-12 Медиммьюн Лимитед Слитые белки на основе gitrl и пути их применения
JP6959229B2 (ja) 2015-10-23 2021-11-02 アポジェニックス アーゲー 一本鎖ｇｉｔｒ受容体アゴニストタンパク質

Also Published As

Publication number Publication date
CN109180804A (zh) 2019-01-11
TW201643184A (zh) 2016-12-16
WO2016126781A4 (en) 2016-10-13
JP2018508233A (ja) 2018-03-29
IL253433A0 (en) 2017-09-28
US9724390B2 (en) 2017-08-08
CA2975596A1 (en) 2016-08-11
EP3253890A4 (en) 2018-06-27
CO2017008047A2 (es) 2018-01-05
US20180021407A1 (en) 2018-01-25
CN107406878A (zh) 2017-11-28
PH12017501372A1 (en) 2017-12-18
WO2016126781A1 (en) 2016-08-11
KR20170108073A (ko) 2017-09-26
MX2017009793A (es) 2017-10-27
BR112017016705A2 (pt) 2018-04-10
AU2016215394A1 (en) 2017-08-03
US10232017B2 (en) 2019-03-19
HK1243741A1 (zh) 2018-07-20
US20160256527A1 (en) 2016-09-08
MA41460A (fr) 2017-12-12
EP3253890A1 (en) 2017-12-13
SG11201706268XA (en) 2017-08-30

Similar Documents

Publication Publication Date Title
EA201791313A1 (ru) Агенты, связывающие суперсемейство рецепторов фактора некроза опухоли (tnfrsf), и их применения
EA201891121A1 (ru) Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
PH12016502267A1 (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
MX2018001787A (es) Proteinas de fusion del ligando de la proteina relacionada con el receptor de factor de necrosis tumoral inducido por glucorticoides (gitrl) y usos de las mismas.
MX2016014647A (es) Proteinas de fusion del ligando de ox40 (ox40l) y sus usos.
EA201790961A1 (ru) Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения
EA201591478A1 (ru) Биспецифические антитела против фно и ил-17
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
EA201790799A1 (ru) Композиции и способы для применения для усиления иммунного ответа и терапии злокачественных опухолей
EA201890443A1 (ru) Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение
EA201891066A1 (ru) Антитела к ror1
EA201991207A1 (ru) Новые агонисты tnfr и их применение
NZ738008A (en) Tigit-binding agents and uses thereof
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
RU2016143383A (ru) Иммуноактивирующая антигенсвязывающая молекула
EA201391789A1 (ru) TNF-АЛЬФА АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, ОБЛАДАЮЩИЕ ПОВЫШЕННЫМ СВЯЗЫВАНИЕМ FcRn
MX2022014695A (es) Anticuerpos anti-gitr y sus usos.
EA201892097A1 (ru) АНТИТЕЛА К ФНО-α И ИХ ФУНКЦИОНАЛЬНЫЕ ФРАГМЕНТЫ
NZ723858A (en) Anti-human ox40l antibodies, uses & methods
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
EA201892440A1 (ru) Антитела к tl1a и их применения
EA201890082A1 (ru) Эпитоп антитела
EA202191785A1 (ru) Антитела к ctla4 и способы их применения